What is the recommended treatment for segmental colitis associated with diverticulosis?

Segmental Colitis Associated with Diverticulosis (SCAD): Treatment Recommendations

For SCAD, initiate treatment with 5-aminosalicylates (5-ASA) as first-line therapy, as most patients (over 80%) achieve long-term remission with this approach alone. 1

Understanding SCAD vs. Diverticulitis

SCAD is a distinct entity from acute diverticulitis—it represents chronic inflammation of the inter-diverticular colonic mucosa, typically in the sigmoid colon, sparing the rectum 2. This is important because the treatment approach differs fundamentally from acute diverticulitis management.

Key distinguishing features:

• Presents with rectal bleeding, diarrhea, and abdominal pain
• Characteristically lacks fever, leukocytosis, and rectal involvement 3
• Occurs predominantly in older adults (mean age ~64 years) with male predominance (58.7%) 3
• Prevalence of 0.3-1.3% in patients with diverticulosis 3

Treatment Algorithm

Initial Management

Start with 5-aminosalicylates (mesalamine) as first-line therapy. The evidence strongly supports this approach:

• Over 80% of patients achieve long-term resolution with 5-ASA alone 1
• Many patients experience spontaneous remissions even without treatment 4, 1
• Most patients have an entirely benign clinical course 4

For Refractory Cases

If symptoms persist despite 5-ASA therapy:

1. Add corticosteroids for acute flares
2. Consider azathioprine for steroid-dependent disease (particularly in SCAD type D patients who fail to maintain remission) 5
3. Reserve surgical resection only for persistent, chronically active disease unresponsive to medical therapy 1

Disease Subtypes and Prognosis

The clinical course varies by SCAD subtype 5:

• Type A and C: More benign course with better long-term remission rates (83% and 100% respectively with treatment)
• Type B: Moderate course (62.5% remission rate)
• Type D: Most refractory, often requiring repeated steroid courses and immunosuppression (0% continuous remission without escalation)

Continuous maintenance therapy is recommended for types B, C, and D to sustain remission 5. Even type A patients benefit from ongoing treatment, though some may maintain remission without it.

Critical Pitfalls to Avoid

1. Do NOT treat SCAD like acute diverticulitis: Antibiotics are not the primary treatment for SCAD, unlike acute diverticulitis where selective antibiotic use is appropriate 2

2. Do NOT use 5-ASA, probiotics, or rifaximin to prevent diverticulitis recurrence 2—but these agents (particularly 5-ASA) ARE effective for treating SCAD itself 1

3. Perform colonoscopy 6-8 weeks after initial presentation to confirm diagnosis and exclude inflammatory bowel disease, ischemic colitis, or malignancy 2

4. Reassure patients: SCAD does not increase colorectal cancer risk 1 and may actually be associated with lower adenoma rates compared to simple diverticulosis 6

Monitoring and Follow-up

• Most patients respond within weeks to months of initiating 5-ASA therapy
• Long-term maintenance therapy prevents recurrences, particularly in types B and D
• Episodic recurrences may occur but typically respond to the same treatment regimen 1
• If chronic symptoms persist despite treatment, exclude alternative diagnoses with both imaging (CT) and repeat colonoscopy 2

The natural history data spanning up to 20 years demonstrates that SCAD is fundamentally different from inflammatory bowel disease, with most patients achieving sustained remission on simple aminosalicylate therapy alone 1.